Physician profile
Cornelius Walter
NPI 1619948379
$7,833.08
in general payments reported to CMS, 2019-2025
41 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $678 · 2021: $1,856 · 2022: $1,439 · 2023: $1,147 · 2024: $956 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,172.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.16 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $757.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $576.36 | 2019-2025 | |
| Amgen INC. | $496.27 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $450.46 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $439.89 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $392.84 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $314.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.64 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.25 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $304.50 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $272.27 | 2019-2023 | Trintellix |
| Abbott Laboratories | $233.07 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Novartis Pharmaceuticals Corporation | $228.60 | 2021-2025 | |
| Astellas Pharma US INC | $205.42 | 2019-2025 | Veozah, Myrbetriq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $193.95 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $180.27 | 2019-2022 | |
| Exact Sciences Corporation | $161.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $139.95 | 2021-2024 | |
| Amarin Pharma, INC. | $118.96 | 2020-2021 | |
| Daiichi Sankyo INC. | $108.59 | 2021-2025 | Injectafer |
| Esperion Therapeutics, INC. | $93.60 | 2021-2022 | |
| Edwards Lifesciences Corporation | $65.00 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceuticals, INC. | $60.46 | 2021 | |
| Alexion Pharmaceuticals, INC. | $50.50 | 2022-2023 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $37.75 | 2019-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $35.93 | 2023-2024 | Quviviq |
| Ani Pharmaceuticals, INC. | $34.75 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $32.75 | 2025 | Auvelity |
| Boston Scientific Corporation | $29.53 | 2024 | Watchman Flx |
| Sanofi Pasteur INC. | $25.33 | 2019-2020 | |
| Inari Medical, INC. | $24.10 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Xeris Pharmaceuticals, INC. | $23.39 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $23.25 | 2023 | Dexcom G6 Transmitter |
| Corium, LLC | $21.88 | 2022 | |
| Inspire Medical Systems, INC. | $21.29 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $21.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.70 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $14.85 | 2021 | |
| Therapeuticsmd, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelius Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.